Choroidal Neovascularization Market - Global Forecast 2026-2032

The Choroidal Neovascularization Market size was estimated at USD 6.88 billion in 2025 and expected to reach USD 7.36 billion in 2026, at a CAGR of 7.86% to reach USD 11.69 billion by 2032.

Choroidal neovascularization (CNV) is a sight-threatening retinal condition characterized by abnormal blood vessel growth from the choroid through Bruch’s membrane, often leading to leakage, hemorrhage, fibrosis, and central vision loss. It is most commonly associated with neovascular age-related macular degeneration, while also occurring in pathologic myopia, ocular inflammatory disease, angioid streaks, trauma, and inherited retinal disorders. The clinical importance of CNV is increasing as populations age, myopia prevalence rises in many countries, and health systems place greater emphasis on early diagnosis, durable treatment response, and preservation of visual function.

The current CNV care pathway is anchored by multimodal retinal imaging, especially optical coherence tomography (OCT), OCT angiography, fluorescein angiography, indocyanine green angiography, and fundus photography. Anti-vascular endothelial growth factor (anti-VEGF) therapy remains the dominant treatment approach for active CNV, supported by extensive clinical evidence showing improved visual outcomes when disease activity is detected early and managed consistently. At the same time, treatment burden, injection adherence, undertreatment, geographic access gaps, and variable response continue to shape clinical and commercial priorities. As a result, stakeholders are focusing on longer-duration therapies, precision imaging, artificial intelligence-enabled screening, real-world evidence generation, and patient-centric care models to improve outcomes across diverse CNV populations.

The choroidal neovascularization landscape is undergoing transformative change as retinal care shifts from reactive disease management toward earlier detection, individualized treatment intervals, and integrated monitoring. High-resolution OCT has become central to clinical decision-making because it allows physicians to detect subretinal and intraretinal fluid, pigment epithelial detachment, and structural biomarkers that guide retreatment. OCT angiography is strengthening noninvasive vascular assessment by visualizing CNV networks without dye injection, improving suitability for repeated monitoring in patients requiring long-term care.

Treatment strategies are also evolving. Anti-VEGF agents have established the standard for controlling exudative activity, but real-world studies consistently show that outcomes can be affected by missed visits, delayed retreatment, and injection fatigue. This has accelerated interest in durable therapies, treat-and-extend regimens, sustained delivery platforms, biosimilars where approved, and combination approaches targeting inflammation, angiogenesis, and fibrosis. Health systems are also expanding teleophthalmology, community-based retinal imaging, and referral triage programs to address access barriers. Together, these shifts are creating a more data-driven CNV ecosystem in which imaging, adherence, durability, and workflow efficiency are as important as therapeutic efficacy.

Artificial intelligence is becoming an important enabler in choroidal neovascularization care by improving image interpretation, triage, monitoring consistency, and operational efficiency. Validated AI models in retinal disease have demonstrated strong performance in detecting referable retinal abnormalities from fundus images and OCT scans, and similar approaches are being adapted to identify fluid, hemorrhage, pigment epithelial detachment, subretinal hyperreflective material, and other CNV-related features. By assisting clinicians in recognizing disease activity, AI can support faster referral decisions and more consistent follow-up prioritization.

The cumulative impact of AI is particularly relevant in high-volume retina practices and under-resourced settings where specialist availability is limited. Automated segmentation and quantitative fluid analysis can help track treatment response over time, while predictive analytics may support individualized injection intervals and risk stratification. AI-enabled remote monitoring and teleophthalmology can also reduce unnecessary clinic visits while flagging patients needing urgent assessment. However, responsible adoption requires transparent validation across diverse populations, regulatory compliance, clinician oversight, data privacy safeguards, and workflow integration. In CNV, AI is best positioned as a clinical decision-support tool that enhances retinal specialist capacity rather than replacing expert judgment.

Asia-Pacific is a critical region for choroidal neovascularization due to its aging population base, high burden of myopia in East and Southeast Asia, and expanding retinal imaging infrastructure in urban centers. China, Japan, South Korea, Australia, India, and ASEAN markets show rising demand for OCT-based diagnosis and anti-VEGF treatment access, although reimbursement, rural access, and specialist distribution vary widely. High myopia prevalence in several Asian populations increases attention on myopic CNV, making early detection and referral pathways especially important.

North America demonstrates mature adoption of retinal imaging, anti-VEGF therapy, treat-and-extend protocols, and real-world evidence systems. The United States and Canada benefit from established retina specialist networks and broad clinical use of OCT, while continuing to address treatment burden, insurance authorization complexity, and access disparities among older adults and underserved communities. Latin America is advancing CNV care through increasing availability of retinal specialists and imaging in major cities, with Brazil and Mexico serving as important access hubs; however, uneven reimbursement and geographic barriers can delay diagnosis and consistent treatment.

Europe benefits from strong ophthalmology networks, national health systems, and evidence-based retinal disease guidelines, particularly across the European Union and the United Kingdom. Germany, France, Italy, and Spain show extensive anti-VEGF utilization and structured macular disease services, while Eastern European access can be more variable. The Middle East is investing in specialty eye care and hospital infrastructure, especially in GCC countries, where diabetes and aging populations increase broader retinal service demand. Africa faces the greatest access constraints, including limited retina specialists, uneven OCT availability, and late-stage presentation in many settings, making teleophthalmology, workforce training, and referral system strengthening essential for CNV outcomes.

ASEAN represents a rapidly evolving group for choroidal neovascularization care, shaped by high myopia prevalence in several member states, expanding private ophthalmology services, and growing investment in diagnostic imaging. Urban centers increasingly use OCT and anti-VEGF therapy, while rural and island communities continue to face referral delays and affordability barriers. The GCC is characterized by strong hospital investment, advanced specialty care in major cities, and growing emphasis on retinal disease management as populations age and chronic disease programs expand. These countries are well positioned to adopt AI-assisted imaging triage and integrated ophthalmology pathways, provided that data governance and workforce training keep pace.

The European Union provides a structured environment for CNV diagnosis and treatment through regulatory harmonization, public health systems, and clinical guideline adoption. EU member states also support real-world data initiatives that can improve understanding of treatment durability, adherence, and outcomes. BRICS countries show substantial heterogeneity: China and India face large population-level demand and access variation, Brazil and South Africa contend with uneven specialist distribution, and Russia has a developed ophthalmology base with regional differences in care availability. The G7 group generally demonstrates advanced access to retinal imaging, established anti-VEGF protocols, and strong clinical research capacity, although patient adherence and healthcare affordability remain policy priorities in several systems. NATO countries overlap substantially with North American and European retinal care networks, where procurement standards, health system resilience, and digital health adoption can influence availability of advanced imaging, biologic therapies, and secure AI-enabled care infrastructure.

The United States leads in clinical adoption of OCT-guided CNV management, anti-VEGF treatment protocols, retina subspecialty care, and real-world evidence generation, while payer authorization, treatment burden, and rural access remain key challenges. Canada has a well-established retinal care infrastructure supported by provincial healthcare systems, with continued focus on timely specialist referral and equitable access across remote communities. Mexico is expanding retinal imaging and anti-VEGF access in major urban centers, although out-of-pocket costs and uneven public-sector availability can affect continuity of care. Brazil has a strong ophthalmology base in metropolitan regions and increasing CNV awareness, but regional disparities influence diagnosis and treatment consistency.

The United Kingdom has structured macular disease pathways supported by national clinical guidance and high OCT utilization, with service capacity and injection clinic demand remaining important operational concerns. Germany, France, Italy, and Spain maintain advanced retinal services and broad use of evidence-based CNV treatment, supported by specialist networks and established reimbursement frameworks. Russia has significant ophthalmology expertise in major cities, but regional differences in advanced imaging and treatment access can affect patient pathways. China is experiencing rapid expansion in retinal imaging capacity and specialist services, with aging demographics and high myopia prevalence reinforcing the need for scalable CNV detection and management. India faces a dual challenge of growing retinal disease demand and wide rural-urban access gaps, making teleophthalmology and affordable imaging strategies especially important.

Japan has a high aging population and a well-developed ophthalmology system, making neovascular age-related macular degeneration and myopic CNV important clinical priorities. Australia benefits from strong specialist care and imaging access in urban areas, while geographic dispersion creates a continuing need for remote screening and referral coordination. South Korea has advanced digital health infrastructure, high myopia prevalence, and strong adoption of retinal imaging, positioning the country for continued integration of AI-supported CNV assessment and precision monitoring.

Industry leaders should prioritize solutions that reduce treatment burden, improve early detection, and support equitable access to retinal care. Durable therapeutic approaches, optimized delivery systems, and evidence-based treat-and-extend strategies should be aligned with real-world adherence patterns rather than idealized trial conditions. Developers of diagnostic technologies should focus on interoperable OCT and OCT angiography workflows, automated disease activity quantification, and AI tools validated across age groups, ethnicities, imaging devices, and CNV subtypes.

Healthcare providers and payers should strengthen referral networks between primary eye care, optometry, general ophthalmology, and retina specialists to shorten time from symptom onset to treatment. Investment in teleophthalmology, mobile imaging, and remote monitoring can expand access in underserved regions, particularly where retina specialist density is limited. Stakeholders should also generate high-quality real-world evidence on visual outcomes, injection frequency, safety, adherence, and patient-reported outcomes. Patient education remains essential, especially for recognizing metamorphopsia, sudden central vision changes, and the importance of maintaining scheduled anti-VEGF visits. Organizations that combine clinical durability, imaging intelligence, access strategy, and patient engagement will be better positioned in the CNV ecosystem.

This executive summary is developed using a structured secondary research approach focused on verified medical, regulatory, and scientific sources. The analysis draws on peer-reviewed ophthalmology literature, clinical practice guidelines, public health resources, regulatory documentation, disease education materials, and real-world evidence studies related to choroidal neovascularization, neovascular age-related macular degeneration, myopic CNV, retinal imaging, anti-VEGF therapy, teleophthalmology, and AI-enabled retinal assessment.

The methodology emphasizes evidence triangulation across clinical trial findings, observational research, health system guidance, and regional care infrastructure indicators. Insights are synthesized qualitatively to identify disease drivers, diagnostic and treatment trends, technology shifts, regional access patterns, and strategic implications. The analysis intentionally excludes market sizing, market share, market estimation, and forecasting. All conclusions are framed around clinically validated trends, healthcare access realities, and documented innovation pathways in CNV diagnosis and management.

Choroidal neovascularization remains a major cause of irreversible central vision loss, but advances in retinal imaging, anti-VEGF therapy, AI-assisted analysis, and patient-centered care models are improving the ability to detect and manage active disease. The strongest opportunities are emerging where clinical efficacy is paired with durability, workflow efficiency, adherence support, and scalable access.

Regional and country-level differences in aging, myopia prevalence, specialist availability, reimbursement, and imaging infrastructure will continue to shape CNV care pathways. Industry stakeholders that invest in validated AI, durable treatment solutions, real-world evidence, equitable access programs, and integrated retinal care networks can help reduce preventable vision loss while supporting more sustainable CNV management worldwide.